Carlos David Esteban Nieto

Caixa Capital Risc SGEIC SA (Caixa Capital Risc) is a venture capital armof Criteria Caixa SA founded in 2002. The firm is headquartered in Barcelona, Spain with additional offices in Madrid.

Omnia Molecular SL engaged in the designing of anti-infective pharmaceuticals. The firm used its proprietary platform to synthesize and develop novel drugs targeted at infections such as mycosis and tuberculosis. The company was founded by Lluís Ribas de Pouplana and Juan Gargallo Costa in 2005 and was headquartered in Barcelona, Spain.

Sagetis Biotech SL designs and develops drug-delivery technologies. Its polymeric-based platforms are designed to address areas such as" delivery through the blood-brain barrier, genetic material transfection, and tissue regeneration. The company was founded by David Horna, Eduard Diviu Terradas and Salvador Borros Gomez on April 14, 2010, and is headquartered in Barcelona, Spain.

iMiCROQ SL develops pathogen detection systems for the food safety industry. Its diagnostic systems test for the presence of listeria, staphylococcus, salmonella, and airborne contaminants. The company was founded by Carlos Arias, Viviana Duarte, Diego Bejarano, Pablo Lozano, and Ioanis Katakis on April 23, 2010, and is headquartered in Tarragona, Spain.

Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain.

ProRetina Therapeutics SL develops drugs for the treatment of retinal conditions. Its pipeline includes PRO-001 used for the treatment of retinitis pigmentosa and PRO-015 is a gene vector that codes the human proinsulin gene indicated for Retinitis Pigmentosa. The company was founded by Stuart Medina in 2007 and is headquartered in Noain, Spain.